Laila Pharmaceutical Pvt. Ltd.

Laila Pharmaceuticals Pvt. Ltd.

Laila Pharmaceuticals Private Limited

Anitha Krishnan Nair

Ganga Raju Gokaraju

Rama Raju Gokaraju

Ramchand Nanappan Chaniyilparampu

Trimurtulu Golakoti

Kiran Bhupathiraju

Kavitha Parthasarathy

Anuj Kapoor

Venkateswarlu Somepalli

Kiran Bhuphatiraju

Nirvanashetty Somashekara

Venkata Narashimha Siva Rama Raju Mandapati

Madhavi Mungala

Malliga Raman Murali

Bhupathiraju Kiran

A pharmaceutical composition for nasal administration comprising: a nanoemulsified curcumin component; a liquid medium for the curcumin component; and a pharmaceutically acceptable excipient. The curcumin component is a natural curcuminoid, a synthetic curcuminoid, a metabolite of a natural or synthetic curcuminoid, or a mixture thereof. The excipient is effective in increasing the bioavailability of the curcumin component.

Curcuminoids and its metabolites for the application in allergic ocular/nasal conditions

The invention discloses a compound of formula (I) wherein, at least one of R, R, Rand Ris &#x2014;C(&#x2550;O)Rand R, RRand Rare H or CHand Ris alkyl or alkenyl group. The alkenyl group have one or more number of double bonds either in cis form or trans form or both. In R, where n is 12 to 30 carbons; and pharmaceutically acceptable salt thereof. The said alkenyl groups are preferably selected from the group consisting of eicosapentaenoic acid (EPA) or DHA (docosahexaenoic acid). This invention further discloses processes for their preparation of compounds of formula I and pharmaceutical compositions that contain these compounds. 

Orally active curcuminoid compounds

A process for nanomulsification of highly lipophillic polyphenols compounds using non-ionic surfactant and a non-ionic co-solvent with the help of sonar energy, to enhance the aqueous solubility is disclosed herein.

Process for nanoemulsification of curcumin and derivatives of curcumin

Nanoemulsified topical formulation comprising curcumin, tetrahydroxycurcumin (BDMC) and curcuminoid either alone or in combinations in an amount of 0.001% to 50% together with one or more pharmaceutically, nutraceutically or dietically acceptable excipient(s) or inactive ingredients, useful for the treatment of inflammation, various skin and oral disorders, mucosal disorders and other diseases associated or related thereof.

Topical formulation(s) for the treatment of inflammation, skin and mucosal disorders and other diseases thereof

Growing community of inventors

Chennai, India

Anitha Krishnan Nair